Fuse Medical Inc. began the official launch of the FuseChoice Dermal Matrix line (FuseChoice Derm). This is the latest addition to Fuse’s comprehensive biologics portfolio.
 
Dermal matrices have a significant track record in sports medicine and wound care markets for applications such as supplemental support, protection, reinforcement, and covering of a tendon or soft tissue. As technology has advanced, Fuse is now able to offer thicker options for a broader range of solutions with practical storage options and a longer shelf-life.
 
FuseChoice Derm has been developed by using a proprietary process to preserve the inherent properties of key extracellular matrix molecules, such as collagen and elastin, while maintaining excellent tensile strength to maintain its framework with intact vascular channels.
 
“We are excited about this new addition to the Fuse biologics portfolio,” commented Christopher C. Reeg, CEO of Fuse. “While there are several dermal matrices on the market, we believe the composition, versatility, and safety of FuseChoice Derm is the perfect combination of properties for tendon and soft tissue augmentation.”
 
Available in two sizes and three different thicknesses, FuseChoice Derm is unique from other dermal matrices on the market by offering distinctive qualities such as no up-front preparation, a longer shelf life, clearly differentiated indication markers for placement, and storage at ambient temperature.
 
Reeg further added, “We are committed to adding both proven and innovative products to our comprehensive portfolio of products within our spine, total joint, upper and lower extremities, sports medicine, and biologics divisions. Adding new products, such as FuseChoice Derm, demonstrates that our top priority at Fuse remains to provide effective solutions for today’s clinical challenges and assist with improving surgical outcomes.”